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Summary
In a clinical trial where cattle were
either given Excede® or not on arrival,
ADG increased and F:G was numerically improved for cattle that received
Excede compared to control cattle. There
were no differences between initial or
final BW, or DMI observed during the
receiving period due to the administration of Excede. The incidence of bovine
respiratory disease (BRD) for the 32
days of the study was 4.4% for cattle
that received Excede at arrival and
was different compared to the control
cattle which was 12.2%. The correlation
(-0.157) between DMI and morbidity observed in this study was not significant. Metaphylactic treatment with
Excede improved ADG and effectively
reduced the cumulative incidence of
BRD during the study.
Introduction
Controlling BRD among incoming
calves using metaphylaxis (mass medication of cattle with antibiotics at
feedyard arrival) may be an important
management option for veterinarians
and cattle producers. A previous study
evaluated the effect of administration of a long-acting formulation of
ceftiofur crystalline free acid (Excede®
Sterile Suspension, Pfizer Animal
Health, New York, N.Y.) at arrival, or
at revaccination (16 to 27 days after
arrival) on morbidity, mortality, and
BW gain of calves (2007 Nebraska Beef
Report, pp. 68-70). In this study, calf
morbidity from BRD was predominantly within the first 10 to 14 days.
Excede administered at arrival sig-

nificantly reduced (P<0.01) the incidence of BRD compared to treatment
at revaccination. A -0.22 correlation
(P < 0.01) was observed between the
proportions of steers pulled for BRD
treatment and daily DM offered.
However, DMI was restricted initially
with ad libitum intakes after day 10.
The objective of the current study
was to determine the effect of administering Excede at feedlot arrival on
morbidity, mortality, BW gain, and
the correlation of DMI to pen morbidity rates during the first 30 to 35
days of the feedlot receiving period.
Procedure
Two treatments were evaluated
within the feedlot receiving system: 1)
control (no arrival treatment) with no
post treatment interval (PTI) observed
(CONTROL), or 2) Excede® Sterile
Suspension on arrival using the base
of the ear as the injection site with a
PTI of 7 days observed (EXCEDE). A
total of 842 steer calves received at the
University of Nebraska Agricultural
Research and Development Center
between Oct. 17 and Oct. 29, 2006,
were used in this experiment. Steers
were a mixture of “ranch-direct” and
“auction market” sources. Steers were
housed by treatment group and pens
sharing a water tank were assigned
to the same treatment in order to
minimize environmental cross-exposure, or cross-protection. Fifty-two
feedlot pens housed between 12 and
20 head/pen to supply 26 replications
per treatment. Pens were blocked by
arrival day (6 blocks). Steers received
ad libitum intake of a typical feedlot
receiving diet containing (DM basis)
27% dry rolled corn, 35% alfalfa hay,
35% wet corn gluten feed, and 3%
supplement containing 135 mg/steer
daily Deccox® (Alpharma Inc., Fort
Lee, N.J.) and 200 mg/steer daily
Rumensin (Elanco Animal Health,
Greenfield, Ind.). Steers also received
long-stem grass hay (3.4 lb/head/day,
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DM basis), which was removed after
day 2.
Steers were assigned to treatment
based on processing order on arrival,
with every other animal assigned to
each treatment. Only calves that were
large framed and weighed more than
550 lb were assigned on this experiment as all of these calves were designated as “calf-feds.” Steers’ ID tags
were notched to identify treatment
assignment. Calves were processed on
arrival by receiving three separate tags
for individual identification including
an electronic ID, panel tag, and metal
clip tag. Calves were weighed and vaccinated with the following at feedlot
arrival: BoviShield™ Gold 5, Somubac®, and Dectomax® Injectable (Pfizer
Animal Health). All calves with horns
were dehorned or tipped as needed.
Intact bull calves were excluded from
this study. Calves were weighed and
revaccinated at 10-14 days after arrival
which included vaccination with Somubac/Ultrabac® 7 and a second dose
of BoviShield Gold 5. Calves were individually weighed off trial after 32 days
(range 30-35 days) following a 5-day
limit-fed period to minimize variation
due to gut fill.
All pens were evaluated by the
same animal health personnel within
the same day to provide equivalent
evaluation across treatments. Calves
categorized as sick by the cattle crew
were pulled, symptoms assessed, rectal temperature recorded, and BRD
cases treated with Draxxin® Injectable
Solution (Pfizer Animal Health, New
York, N.Y.). When sick calves were
treated, their panel ID tag was marked
to prevent retreating. Animals were
returned to home pens as soon as possible after treatment. A PTI of 7 days
was honored after treatment with
Draxxin before another treatment
could occur. Any animals that were
pulled for reasons other than respiratory disease were treated according to
UNL feedlot SOPs.
(Continued on next page)
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Table 1. Effects of administration of Excede at arrival on performance during the 32-day receiving
period.
CONTROL

EXCEDE

SEM

P-Value

Results for All Animals Using Pen as the Experimental Unit
Initial BW, lb
Revac BW, lba
Final BW, lb
DMI, lb/day
ADG, lb
F:Gb

614
659
686
13.7
2.20
6.21

610
4
663	
5
687
5
14.0
0.2
2.37
0.07
5.88		

0.32
0.51
0.75
0.13
0.02
0.07

Results Excluding 71 Animals Treated for BRD
Initial BW, lb
Revac BW, lba
Final BW, lb
DMI, lb/day
ADG, lb
F:Gb

615
660
686
13.7
2.19
6.25

aRevac BW = Revaccination BW.
bAnalyzed as gain:feed, reciprocal

of feed conversion.

610
4
663	
5
688
5
14.0
0.2
2.40
0.08
5.81		

0.22
0.58
0.77
0.13
<0.01
0.02

Treatment Incidence Density
12.0

# new cases/1,000 animals-days

Initial BW, revaccination BW, final
BW, ADG, DMI, feed:gain ratio, morbidity and mortality were measured.
Initial BW was based on BW recorded
at arrival and was assumed to be a
shrunk weight. Final BW was based
on the average of 2-day consecutive
weights recorded at the end of the trial
after a 5-day limit-feeding period to
minimize variation due to gut fill.
Body weight, ADG, DMI, F:G, and pull
rate data using pen as the experimental unit were analyzed using the Proc
MIXED procedure of SAS (Version
9.1, SAS Inc., Cary, N.C.) with arrival
(and source) as a blocking criteria
and antibiotic treatment as a fixed
effect. The Proc CORR procedure of
SAS (Version 9.1, SAS Inc.) was used
to correlate DMI and morbidity. The
Proc GENMOD procedure of SAS
(Version 9.1, SAS Inc.) was used to
analyze binary respiratory disease
morbidity outcomes in a generalized
estimating equations model using
the logit link and accounting for correlation of animals within pen. An
animal was classified as a respiratory
disease observation for the trial if the
animal was treated for respiratory disease by the animal health personnel.

10.0
8.0
Control

6.0

Excede
4.0
2.0

Results
0.0
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Figure 1. Incidence density of first pulls for BRD by treatment and days on trial.
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There were no significant differences (P > 0.05) between initial BW
(612 ± 4 lb), revaccination BW (661
± 5 lb), final BW (687 ± 5 lb), or DMI
(13.9 lb/day) observed in this study
due to administration of Excede
(Table 1). ADG over the study period
was 8% higher for cattle that received
Excede on arrival than for those that
did not. Cattle that received Excede
on arrival had a greater (P = 0.02)
ADG and a numerically improved
(P = 0.07) F:G ratio compared with
CONTROL cattle. A total of 71
animals were treated for BRD in this
study, 19 from EXCEDE and 52 in
CONTROL. Also, there were not any
animals in this study that had to be
retreated or that died. With treated
animals removed from the dataset,
EXCEDE cattle continued to have significantly greater (P < 0.01) ADG and
significantly improved (P = 0.02) F:G

0.12
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0.04
0.02
0.00

Control

Excede

Figure 2. Cumulative incidence of BRD for the study period by treatment.
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ratio compared to CONTROL cattle.
There were no differences observed for
BW or DMI. The correlation (-0.157)
between DMI and pen-level incidence
of BRD morbidity for the study period
was not significant (P = 0.27).
CONTROL and EXCEDE cattle
were first pulled for BRD at different
periods of time after receiving (Figure
1). CONTROL cattle had a higher
incidence of BRD at the beginning of
the study, mainly between day 0 and
day 10; however, EXCEDE cattle were
not eligible for BRD treatment until 8

days after enrollment into the study.
The incidence of BRD for cattle treated with Excede peaked between days
21-25. The only variable that significantly explained the incidence of BRD
was metaphylactic treatment with
Excede (odds ratio = 0.33, P < 0.01).
Cumulative incidence of BRD for the
study period was 4.4% for cattle that
received Excede at arrival and 12.5%
for CONTROL cattle. Cattle that received metaphylactic treatment were
64% less likely to be treated for BRD
than CONTROL cattle.
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In conclusion, metaphylatic treatment with Excede at arrival in the
feedlot effectively reduced the incidence of BRD by 64%, and also improved ADG 8% during the receiving
period compared to no metaphylaxis.
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